VAS
APGE icon

Vestmark Advisory Solutions’s Apogee Therapeutics APGE Stock Holding History

Vestmark Advisory Solutions’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.06M Buy
15,547
+2,900
+23% +$261K 0.02% 702
2026
Q1 		$1.06M Sell
12,647
-27
-0.2% -$1.96K 0.01% 845
2025
Q4 		$957K Buy
+12,674
New +$798K 0.01% 814

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Vestmark Advisory Solutions's APGE Position: Q2 2026 in Review

Vestmark Advisory Solutions increased its Apogee Therapeutics (APGE) stake by 23% in Q2 2026, buying an estimated $261K and bringing the position to 15,547 shares worth $2.06M. The position accounts for 0.02% of the portfolio, ranked #702.

Vestmark Advisory Solutions first reported a position in APGE in Q4 2025 and has held it in 3 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Vestmark Advisory Solutions held 15,547 shares of Apogee Therapeutics worth $2.06M as of Q2 2026.
  • Vestmark Advisory Solutions bought 2,900 Apogee Therapeutics shares in Q2 2026, an estimated $261K.
  • Apogee Therapeutics made up 0.02% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #702 holding.
  • Vestmark Advisory Solutions first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.